|
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Clinical research trials and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia. Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia clinical trial. Human subjects frequently get the finest healthcare available for their Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia  Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
For Condition: myelodysplastic and myeloproliferative diseases,plasma cell neoplasm,chronic myeloproliferative disorders,childhood Hodgkin's lymphoma,Lymphoma,Leukemia
Status: Recruiting
Sponsor(s): Roswell Park Cancer Institute , National Cancer Institute (NCI)
Synopsis: RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by donor peripheral stem cell transplantation in treating patients who have hematologic cancer or aplastic anemia.
Details: OBJECTIVES: - Determine the safety and toxic effects of nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with a hematologic malignancy or aplastic anemia. - Determine clinical response and overall outcome of patients treated with this regimen. - Determine the incidence of graft-vs-tumor effect, graft-vs-host disease, and chimerism in patients treated with this regimen. OUTLINE: - Matched related and unrelated donor transplantation: - Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine IV over 30 minutes on days -5 to -1. - Cord blood transplantation: - Patients receive the same regimen as above plus anti-thymocyte globulin IV over 4 hours on days -3 to -1. - Matched related and unrelated donor transplantation: - Patients receive oral tacrolimus (or IV) once daily and oral mycophenolate mofetil (MMF) (or IV) twice daily on days -1 to 60 followed by tapering* of this regimen. Patients then receive methotrexate IV on days 1, 3, and 6. NOTE: *This regimen is tapered from days 30-60 if donor chimerism of T-cells is 100%. MMF is then stopped and tacrolimus is tapered by 25% every 10 days and discontinued by day 90 if no GVHD develops. - Cord blood transplantation: - Patients receive tacrolimus and MMF in the same regimen as above plus methylprednisolone twice daily on days 1-19 or until blood counts recover. - Allogeneic stem cell reinfusion: Patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0. Patients then receive sargramostim (GM-CSF) subcutaneously daily beginning on day 7 and continuing until blood counts recover. - Donor lymphocyte infusion (DLI): Patients not converting to 100% donor T-cell chimerism by day 120 and showing signs of progresson of disease after tacrolimus and MMF withdrawal may receive DLI every 8 weeks for up to 3 infusions. Cord blood recipients do not receive DLI. Patients are followed at day 100-120, every 3 months for 2 years, and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 30-60 patients will be accrued for this study within 6-7 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 5 Years/70 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of aplastic anemia - Severe disease - Failed at least 1 course of standard immunosuppressive regimen with cyclosporine and anti-thymocyte globulin OR - Histologically confirmed hematologic malignancy including the following: - Acute leukemia - Any of the following types: - Acute myeloid leukemia (AML) with antecedent myelodysplastic syndromes - Secondary AML - AML with high-risk cytogenetic abnormalities - Acute lymphoblastic leukemia with high-risk cytogenetic abnormalities - Resistant or recurrent disease after combination chemotherapy with at least 1 standard regimen OR - In first remission at high risk of relapse - Chronic myelogenous leukemia - Chronic phase meeting at least 1 of the following criteria: - Failed imatinib mesylate - Failed interferon after at least 6 months of treatment with minimum of 21 million units of interferon per week - Unable to tolerate interferon - Accelerated phase (blasts less than 20%) - Myeloproliferative and myelodysplastic syndromes - Myelofibrosis (after splenectomy) - Refractory anemia - Refractory anemia with excess blasts - Chronic myelomonocytic leukemia - Lymphoproliferative disease - Chronic lymphocytic leukemia - Symptomatic disease after first-line chemotherapy - Low-grade non-Hodgkin's lymphoma (recurrent or persistent) - Symptomatic disease after first-line chemotherapy - Multiple myeloma - Progressive disease after autologous stem cell transplantation - Waldenstrom's macroglobulinemia - Failed 1 standard regimen - Non-Hodgkin's lymphoma meeting the following criteria: - Intermediate or high grade - Controlled and chemosensitive disease - First remission lymphoblastic or small non-cleaved cell lymphoma at high risk of relapse - Hodgkin's lymphoma - Relapsed and chemosensitive disease - Not eligible for standard myeloablative allogeneic stem cell transplantation - Availability of any of the following donor types: - Related donor matched at 5 or 6 HLA antigens (A, B, DR) - Unrelated donor fully matched by molecular analysis at A, B, DRB1, and DQB1 loci - Single antigen mismatch at C allowed - Cord blood that is 4, 5, or 6 match with recipient HLA antigens (A, B, DR) NOTE: No syngeneic donors permitted - No uncontrolled CNS disease (for hematologic malignancies) NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age - 5 to 70 (if related donor transplantation) - 5 to 55 (if unrelated donor transplantation) Performance status - Karnofsky 60-100% Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Bilirubin less than 3 times normal - Alkaline phosphatase less than 3 times normal - AST/ALT less than 3 times normal - No Child's class B or C liver failure Renal - Creatinine clearance greater than 40 mL/min Cardiovascular - Cardiac ventricular ejection fraction at least 35% by MUGA - No cardiovascular disease Pulmonary - DLCO at least 40% of predicted, corrected for hemoglobin and/or alveolar ventilation Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV antibody negative - No uncontrolled diabetes mellitus - No active serious infection - No other disease that would preclude study therapy - No other concurrent malignancy except non-melanoma skin cancer - No concurrent serious psychiatric illness PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - At least 6 months since prior autologous bone marrow transplantation (BMT) - At least 12 months since prior allogeneic BMT Chemotherapy - See Disease Characteristics - At least 4 weeks since prior chemotherapy Endocrine therapy - Not specified Radiotherapy - At least 4 weeks since prior radiotherapy Surgery - At least 4 weeks since prior surgery
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ArifAlam, Study Chair, Roswell Park Cancer Institute
Roswell Park Cancer Institute *Recruiting*
Buffalo, New York, 14263-0001
United States
Recruiting Arif Alam 716-845-8707
Additional Information:
Study ID Numbers: CDR0000269673; RPCI-RP-0105
Study Start Date:
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00053989
Other Leukemia Studies:
1. Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
2. Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
3. Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4. Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
5. BCX-1777 in Treating Patients With Refractory Hematologic Cancer
Related Studies:
Other Leukemia Clinical Trials
Other New York Clinical Trials
Other Buffalo Clinical Trials
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
|
|
|
|
|
|
|
|
